SK bioscience Invests $3M in U.S. Biotech Fina Biosolutions

SK Capital to Invest in Swixx BioPharma in Deal Valued at Over €1.5 Billion

December 15, 2025

Healthcare Services

SK Capital Partners, through an affiliate, reached a definitive agreement to invest in Swixx BioPharma AG as the company looks to accelerate its next phase of growth and global expansion. The transaction values Swixx at more than €1.5 billion, with Swixx co-founders and CEO/CFO retaining significant ownership and existing investors HBM Healthcare Investments and Mérieux Equity Partners remaining shareholders.

Bain Capital Life Sciences Leads $200M Growth Investment in Serán Bioscience

September 17, 2024

Pharmaceuticals

Bain Capital Life Sciences led a strategic growth investment of more than $200 million in Serán Bioscience, with existing investor Vivo Capital remaining a key shareholder. The capital will fund a new commercial-scale manufacturing campus in Bend, Oregon, expanding Serán's development, analytical and commercial manufacturing capabilities across multiple drug delivery modalities.

Asahi Kasei Medical to Acquire Bionova Scientific

April 14, 2022

Healthcare Services

Asahi Kasei Medical, through a U.S. subsidiary, has agreed to wholly acquire Bionova Scientific, LLC, a U.S.-based biopharmaceutical CDMO providing contract process development and GMP-compliant contract manufacturing services. The acquisition will add CDMO capabilities to Asahi Kasei Medical’s existing bioprocess business and broaden know-how-driven services for next-generation antibody drugs.

BYG4lab to Acquire Finbiosoft with Support from Keensight Capital

March 14, 2024

Software

BYG4lab has signed an exclusivity agreement to acquire Finbiosoft, a Finland-based provider of quality and laboratory software for medical laboratories, with the support of Keensight Capital. The deal is intended to broaden BYG4lab's product capabilities, add Finbiosoft's technical team, and expand the group's geographic footprint across Europe and into the United States while enabling cross-selling to an expanded client base.

Keensight-backed Biovian and 3P Biopharmaceuticals Merge to Form 3PBIOVIAN

February 1, 2024

Biotechnology

Biovian and 3P Biopharmaceuticals have combined under their common shareholder Keensight Capital to form 3PBIOVIAN, a pan‑European biologics CDMO offering end‑to‑end development and manufacturing across microbial and mammalian protein expression, viral vectors, cell therapy and plasmid DNA. The combined group will operate sites in Pamplona‑Noáin (Spain) and Turku (Finland), maintain a commercial office in Boston, and employ over 500 professionals with gross sales above €75m; ERES IV (advised by Elyan Partners) and Sodena will remain minority shareholders alongside Keensight.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.